FDA Approves Moderna RSV Vaccine mRNA-1345 for Older Adults

The U.S. Food and Drug Administration (FDA) has approved mRNA-1345, Moderna's messenger RNA vaccine targeting respiratory syncytial virus (RSV), for adults aged 60 years and older. The approval follows a comprehensive FDA review of Phase 3 clinical trial data demonstrating significant efficacy in preventing RSV-associated lower respiratory tract disease in the target population. This mRNA-1345 authorization represents a key milestone in vaccinology and addresses a substantial unmet medical need, as RSV remains a leading cause of hospitalization and morbidity in older adults.

Drug Overview

mRNA-1345 is an mRNA-based vaccine developed by Moderna that encodes the stabilized prefusion form of the respiratory syncytial virus F glycoprotein. The vaccine leverages Moderna's mRNA technology platform, the same foundational approach used in their authorized COVID-19 vaccines. By encoding the prefusion F protein, mRNA-1345 is designed to elicit robust neutralizing antibody responses and cellular immunity against RSV. The vaccine is indicated for immunization of adults aged 60 years and older to prevent respiratory illness caused by RSV, a major pathogen in infectious disease management in older populations.

IntelligenceRegulatory Impact▾

FDA are the agencies to watch. Regulatory relevance reads medium for infectious disease, with mRNA-1345 most exposed to upcoming decisions. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Clinical Insights

The FDA approval was supported by data from a large, randomized, placebo-controlled Phase 3 clinical trial evaluating mRNA-1345 in adults aged 60 years and older. [Source: U.S. Food and Drug Administration] The trial met its primary efficacy endpoint, demonstrating significant efficacy in preventing RSV-associated lower respiratory tract disease. The vaccine exhibited a favorable safety and tolerability profile consistent with class-typical mRNA vaccine adverse events. Commonly reported adverse events were mild to moderate in severity and transient, including injection site reactions, fatigue, headache, and myalgia. The Phase 3 safety review identified no unexpected safety signals, supporting the favorable benefit-risk profile that informed the FDA's approval decision.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Regulatory Context

mRNA-1345 was reviewed by the FDA through submission of a Biologics License Application (BLA), the regulatory pathway for vaccines and other biological products. The approval followed comprehensive evaluation of preclinical, Phase 1, Phase 2, and Phase 3 clinical data by the FDA's Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER). Given the significant public health burden of RSV in older adults and the substantial unmet medical need for an effective preventive vaccine, the FDA prioritized its review of this application. The authorization reflects the agency's determination that mRNA-1345 meets the statutory standards for safety, efficacy, and manufacturing quality required for licensure.

IntelligenceMarket Signals▾

Commercial pull is medium and investment relevance low. Expect implications for infectious disease pricing, access, and launch sequencing.

Market Impact

The FDA approval of mRNA-1345 positions Moderna as a key competitor in the emerging RSV vaccine market for older adults. The vaccine enters a competitive landscape that includes late-stage RSV vaccine candidates from Pfizer and GSK, both targeting the same older adult population. RSV represents a significant disease burden in adults aged 60 and older, with the virus being a leading cause of hospitalization and respiratory morbidity in this age group. The approval of mRNA-1345 provides healthcare systems and older adults with an effective preventive option addressing a previously limited set of RSV prevention strategies. Market potential is substantial given the size of the older adult population in the United States and the high incidence of RSV-associated illness in this demographic.

IntelligenceStrategic Takeaways▾

The FDA has approved Moderna's mRNA-1345 vaccine for respiratory syncytial virus (RSV) in older adults, enhancing protection against this serious respiratory illness.

Future Outlook

Following FDA approval, mRNA-1345 will enter the commercial market for older adults. Moderna may pursue additional clinical studies to evaluate the vaccine's durability of protection, potential use in combination with other vaccines recommended for older adults, or efficacy in immunocompromised populations. Competitive RSV vaccine approvals from Pfizer and GSK are anticipated in coming months, which will shape the evolving RSV vaccine market. Real-world effectiveness data and health economic studies will likely emerge to inform clinical practice guidelines and vaccination recommendations. Label expansions or additional indications may be explored as clinical evidence accumulates post-approval.

Frequently Asked Questions

References

1. U.S. Food and Drug Administration. Center for Biologics Evaluation and Research. Approval of mRNA-1345 (Moderna RSV vaccine). [Regulatory decision document; specific date and reference number to be confirmed from official FDA communications].
2. Moderna, Inc. Clinical trial data for mRNA-1345: Phase 3 efficacy and safety results in adults aged 60 years and older. [Company clinical data on file; specific publication or press release to be referenced].
3. National Institute of Allergy and Infectious Diseases (NIAID). Respiratory Syncytial Virus (RSV) and Older Adults. [Public health resource on RSV epidemiology and disease burden].

References

1. U.S. Food and Drug Administration. FDA approval. Accessed 2026-04-07.

Related coverage

• BioNTech doses first patient in Phase 1 pancreatic cancer mRNA vaccine trial
• Moderna mRNA-1083 Phase 3 data show stronger flu and COVID immune response
• Moderna's mRNA-1083 Phase 3 shows stronger flu and COVID immune responses